A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This study is an adaptive Phase III randomized double-blind placebo-controlled trial to
evaluate the efficacy and safety of Proxalutamide (GT0918) in hospitalized adults diagnosed
with COVID-19. The study is a multicenter trial that will be conducted at approximately 80
sites globally. The study will compare GT0918 plus standard of care (SOC) with the placebo
plus SOC. Approximately 1030 subjects will be randomized in a 1:1 ratio to either GT0918 plus
SOC or placebo plus SOC group.